Thinly traded micro cap vTv Therapeutics (NASDAQ:VTVT) is up 21% after hours in response to its announcement that it will release topline data from Part 2 of a Phase 2 clinical trial, Simplici-T1,
evaluating TTP399 as oral adjunctive therapy to insulin in adults with
type 1 diabetes (T1D) at 7:00 am ET on Monday, February 10.
A conference call will follow at 8:30 am.
In June 2019, it announced positive
results from Part 1 of the study that showed treatment with TTP399
lowered HbA1c levels by an average of 8.2% at week 12 compared to a 1.4%
increase in the placebo group.
The company says TTP399 activates
an enzyme called glucokinase (GK) which is a key regulator of glucose
levels, adding that it only activates GK in the liver thereby avoiding
disruption in the interaction between GK and glucokinase regulatory
protein which can lead to hypoglycemia, limited durability of response
and other side effects, problems that have troubled other GK activators.
https://seekingalpha.com/news/3539835-vtv-therapeutics-up-21-after-hours-ahead-of-key-data-readout
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.